Johnson & Johnson
US judge slashes Johnson & Johnson damages in Risperdal case
January 20, 2020Sales and Marketing Big Pharma, Johnson & Johnson, Johnson & Johnson talc powder
A judge in Philadelphia has reduced the amount of damages Johnson & Johnson was ordered to pay by a jury …
No link between talc and ovarian cancer, new study reveals
January 8, 2020Research and Development . Johnson & Johnson, Johnson & Johnson, baby powder, talc, talc powder
Researchers examining data from over 252,000 women have concluded that there is no statistically significant link between the use of …
Johnson & Johnson sued by Washington State for role in the opioid crisis
January 3, 2020Medical Communications Bernie Sanders, Johnson & Johnson, OxyContin, fentanyl, opioid crisis, opioids
The state of Washington sued pharmaceutical company Johnson & Johnson for deceptive marketing that said their opioids were effective for …
J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma
December 9, 2019Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma
Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …
J&J to supply 500,000 Ebola vaccines to fight DR Congo outbreak
November 7, 2019Manufacturing and Production, Research and Development, Sales and Marketing Ebola, Janssen, Johnson & Johnson, pharma
Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply …
J&J must pay $572 million for fuelling opioid crisis in Oklahoma, judge says
August 27, 2019Manufacturing and Production J&J, JJ, Johnson & Johnson, Oklahoma, opioid crisis, opioids, pharma
A judge in Oklahoma has said that Johnson & Johnson must pay $572 million for the part it played in …
J&J’s ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis
July 26, 2019Medical Communications, Research and Development Johnson & Johnson, multiple sclerosis, pharma, ponesimod
New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that …
J&J ‘worse’ than Purdue Pharma expert witness says
June 12, 2019Research and Development J&J, JJ, Johnson & Johnson, Oklahoma, opioid crisis, phamra
The role Johnson & Johnson played in the opioid crisis was ‘in some ways worse’ than that of Purdue Pharma, …
J&J pay $9.9 million to settle surgical mesh implant case
April 23, 2019Manufacturing and Production . Johnson & Johnson, J&J, JJ, Johnson & Johnson, Litigation, washington
Healthcare conglomerate Johnson & Johnson has agreed to pay $9.9 million to settle a Washington state lawsuit over the firm’s …
Janssen closes plant in California, 49 positions axed
April 3, 2019Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, Vacaville, california
Janssen are letting go of 49 employees due to the closure of their plant in Vacaville, California. The Johnson & …
Indian authorities say J&J’s baby shampoo contains ‘harmful ingredients’
April 1, 2019Sales and Marketing Cancer, India, J&J, JJ, Johnson & Johnson, Rajasthan, baby shampoo, formaldehyde
Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful …
J&J bows to PETA pressure and drops forced swim tests in mice
March 21, 2019Medical Communications J&J, JJ, Johnson & Johnson, PETA, animal welfare, pharma
Johnson & Johnson has announced it is to end its practice of forced swim tests on mice, rats and other …
J&J to include prices in drug ads on TV
February 8, 2019Medical Communications J&J, JJ, Johnson & Johnson, Trump, pharma, pricing
US multinational Johnson & Johnson has announced that it will include the price of its medicines in TV commercials for …
J&J shares plummet after asbestos cover up allegations emerge
December 17, 2018Sales and Marketing J&J, JJ, Johnson & Johnson, asbestos, reuters
Shares in American healthcare firm Johnson & Johnson plummeted on Friday after news agency Reuters reported that the New Jersey-based …
NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients
August 10, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma
The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …
